KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform AstriVax will draw on technology developed at the KU Leuven Rega Institute (Belgium) to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various pathogens. Closing on…..
